{
    "nct_id": "NCT03743649",
    "official_title": "Strategies for Persistent Agitated Delirium in Palliative Care",
    "inclusion_criteria": "1. [Patients] Diagnosis of advanced cancer (defined as locally advanced, metastatic recurrent, or incurable disease)\n2. [Patients] Admitted to the acute palliative care unit‡\n3. [Patients] Delirium as per DSM-5 criteria\n4. [Patients] Hyperactive or mixed delirium with RASS ≥1* in the past 24 h despite efforts to treat potential underlying causes\n5. [Patients] On scheduled haloperidol for delirium (≤8 mg in the past 24 h) or required ≥4 mg of rescue haloperidol for agitation in the past 24 h\n6. [Patients] Age 18 years or older\n7. [Caregivers] Patient's spouse, adult child, sibling, parent, other relative, or significant other (partner as defined by patient)\n8. [Caregivers] Age 18 years or older\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. [Patients] History of myasthenia gravis or acute narrow angle glaucoma\n2. [Patients] History of neuroleptic malignant syndrome or active seizure disorder (with seizure episode within the past week)\n3. [Patients] History of Parkinson's disease, Alzheimer's or Lewy body dementia\n4. [Patients] History of prolonged QTc or QTcF interval (>500 ms)† if documented by most recent ECG within the past month\n5. [Patients] History of hypersensitivity to haloperidol or lorazepam\n6. [Patients] On scheduled lorazepam within the past 48 h",
    "miscellaneous_criteria": ""
}